Skip to main
TECH

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 0%
Hold 82%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is a global leader in the life sciences market, with a focus on providing high-quality reagents, instruments, and other products to support research and diagnostics. Its diverse product portfolio and strong presence in key markets, such as the US and Europe, provide a solid foundation for future growth. The recent divestment of its Exosome Diagnostics business and brand consolidation efforts demonstrate proactive self-help initiatives that are driving margin expansion and position the company for a rebound in demand. Its strong position in the emerging cell therapy market and the pending acquisition of Wilson Wolf indicate potential for even greater growth. While there are some risks, such as potential for market share loss to larger competitors and delay in end market recovery, Bio-Techne's strong management team and ongoing focus on self-improvement make it an attractive investment opportunity with a positive outlook.

Bears say

Bio-Techne is currently facing material sustainability challenges in product quality and safety, environmental impact, and human capital management, as well as lacking validated science-based emissions targets. Additionally, the upcoming acquisition of Wilson Wolf, a high growth cell therapy tools company, could bring about transformative opportunities for Bio-Techne. However, there are downside risks, including potential delays in industry demand recovery, loss of market share to competitors, and disappointing progress in the cell therapy market. Furthermore, the company has a mixed track record in M&A and could face potential challenges related to the rise of AI in the life sciences industry.

Bio-Techne (TECH) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 0% recommend Buy, 82% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Hold based on their latest research and market trends.

According to 11 analysts, Bio-Techne (TECH) has a Hold consensus rating as of Aug 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.